Benzinga | Jun 18, 2021 06:17AM EDT

SVB Leerink Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $230

SVB Leerink analyst Marc Goodman maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Outperform and raises the price target from $210 to $230.